These studies indicate that vorinostat exhibits anti-solid tumor activity by upregulating MICA expression in cervical cancer cells through the mediation of the PI3K/Akt pathway, which enhances the susceptibility of cervical cancer cells for NK cell-mediated cytolysis. The gene discussed is PIK3CA; the disease is cervical carcinoma.